Figure 3.

Clinically relevant activities of pentadecanoylcarnitine among 12 primary human cell systems mimicking various disease states. The X-axis lists the quantitative protein-based biomarker readouts measured in each system. The Y-axis represents a log-transformed ratio of the biomarker readouts for the drug-treated sample (n = 1) over vehicle controls (n ≥ 6). The grey region around the Y-axis represents the 95% significance envelope generated from historical vehicle controls. Biomarker activities are annotated when 2 or more consecutive concentrations change in the same direction relative to vehicle controls, are outside of the significance envelope, and have at least one concentration with an effect size > 20% (|log₁₀ ratio|> 0.1). Antiproliferative effects are indicated by a thick grey arrow.